Table 4.
Novel approaches of extending selection criteria.
| Author (year) | Selection criteria | Outcome after LT |
|---|---|---|
| Yang et al. (2006) [131] |
18F-FDG-PET (negative versus positive) |
12% recurrence rate PET− patients 36.5% recurrence rate PET+ patients |
|
| ||
| Kornberg et al. (2009) [132] |
18F-FDG-PET (negative versus positive) |
11.1% recurrence rate Milan Out/PET− 53.8% recurrence rate Milan Out/PET+ |
|
| ||
| Kornberg et al. (2012) [135] |
18F-FDG-PET (negative versus positive) |
5-year recurrence-free survival: 86.2% Milan In 81% Milan Out/PET− 21% Milan Out/PET+ |
|
| ||
| Halazun et al. (2009) [160] | NLR (< versus ≥5) |
5-year recurrence-free survival: 75% in NLR <5 25% in NLR ≥5 |
|
| ||
| An et al. (2012) [163] | CRP (< versus ≥1 mg/dL) |
CRP independent predictor of outcome HR 4.64 recurrence-free survival HR 2.68 overall survival |
|
| ||
| Schwartz et al. (2008) [174] | Allelic imbalance (≤ versus >0.27) |
Tumor recurrence probability at 5 years: 10% in AI ≤0.27 85% in AI >0.27 |
|
| ||
| Jonas et al. (2009) [176] | DNA index (≤ versus >1.5) |
5- and 10-year survival rate in Milan Out 72% and 68% in DNA ≤1.5 26% and 3% in DNA >1.5 |